Home > Offer to Sell > Organic chemicals and Derivatives > Acid, ester and anhydride compounds > Sorafenib tosylate
Sorafenib tosylate
Inquiry
| Post Date: | Dec 07,2018 |
| Expiry Date: | Jun 05,2019 |
| Detailed Description: |
Cas No. :475207-59-1
Use in Cancer
Sorafenib tosylate is approved to treat: •Hepatocellular carcinoma (a type of liver cancer) that cannot be removed by surgery. •Renal cell carcinoma (a type of kidney cancer) that is advanced. •Thyroid cancer in certain patients with progressive, recurrent, or metastatic disease that does not respond to treatment with radioactive iodine. Sorafenib tosylate is also being studied in the treatment of other types of cancer. |
| CAS Registry Number: | 475207-59-1 |
| Synonyms: | ;SORAFENIB-D3;4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide monomethanesulfonate;N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea Tolsylate;Sorafenib TsOH salt; |
| Molecular Formula: | C21H16ClF3N4O3·C7H8SO |
| Molecular Weight: | 637.03 |
| Molecular Structure: | 
|
| Company: | Jinan Chenghishaungda Chemical Co.,LTD [ China ] |
| Contact: | Allen |
| Tel: | 15689693073 |
| Fax: | 0531-58897032 |
| Email: | 3118607598@qq.com |
-
Disclaimer statement:The information and data included above have been realized by the enterprises and compiled by the staff, and are subject to change without notice to you. The Chemnet makes no warranties or representations whatsoever regarding the facticity, accuracy and validity of such information and data. In order to ensure your interest, we suggest you chose the products posted by our gold suppliers or VIP members.
